Thomas J. Herzog, MD, University of Cincinnati Cancer Institute

Articles

Systemic Management of Ovarian Cancer: Closing Thoughts

May 27th 2020

Novel Combination Strategies in Recurrent Ovarian Cancer

May 27th 2020

Recurrent Ovarian Cancer: Novel Agents Under Investigation

May 27th 2020

Bevacizumab’s Role in Recurrent Ovarian Cancer

May 27th 2020

Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

May 27th 2020

PARP Inhibition’s Role in Recurrent Ovarian Cancer

May 27th 2020

Frontline Ovarian Cancer Management: Ongoing Clinical Trials

May 27th 2020

Considerations for the JAVELIN OVARIAN 100 Study

May 27th 2020

Ovarian Cancer: Maintenance Following Frontline Bevacizumab

May 27th 2020

Ovarian Cancer: Updates to NCCN Guidelines

May 27th 2020

Treating Ovarian Cancer Based on HRD Status

May 27th 2020

Ovarian Cancer: What is the Role of HRD Testing?

May 27th 2020

Ovarian Cancer: Factors in Deciding on Maintenance Therapy

May 27th 2020

PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer

May 27th 2020

Practical Applications of PRIMA in Ovarian Cancer Management

May 27th 2020

PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer

May 27th 2020

SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer

May 27th 2020

GOG-0218: Frontline Bevacizumab in Ovarian Cancer

May 27th 2020

Dr. Herzog on the FDA Approval of Olaparib/Bevacizumab as Frontline Maintenance in Ovarian Cancer

May 8th 2020

Thomas Herzog, MD, discusses the data that led to the FDA approval of the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab and whose cancer is associated with homologous recombination deficiency–positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.

Dr. Herzog on the Use of HIPEC in Ovarian Cancer

October 9th 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.